Our Integrated Immunohematology and Immune Dysregulation Program brings together unique expertise in immunology, hematology and BMT. In collaboration with hematology, rheumatology, gastroenterology and other subspecialties, the program offers focused immune and genetic evaluation of patients with either early onset or refractory autoimmune conditions with the goal of providing targeted immune modulatory and biological therapies based on immune profiles and genetics. In patients with immunological or genetically defined immune dysregulation conditions, we also offer BMT as a curative option. The following categories of patients are currently being evaluated in our program:
- Immunohematology: refractory multi-lineage immune cytopenia with or without lymphoproliferation (ALPS and ALPS-like conditions) and post-Rituximab persistent hypogammaglobulinemia
- Very early onset inflammatory bowel disease (IBD), including IPEX and IPEX-like disorders
- Early onset and refractory rheumatologic conditions
- Multisystem autoimmunity
- Auto-inflammatory diseases and periodic fever syndromes
Our Immune Dysregulation research team:
- Shanmuganathan Chandrakasan, MD, Clinical Director